Preservation of bone health in prostate cancer patients during oncological treatment
DOI: 10.22591/magyurol.2023.3.szendroia.110
Authors:
Szendrői Attila dr.1, Szalontai János dr.1, Áts Katalin dr.2
1Semmelweis Egyetem, Urológiai Klinika és Andrológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
2Józsefvárosi Szt. Kozma Egészségügyi Központ (igazgató: Koroknai András dr.)
Summary
The first-line systemic treatment of prostate cancer is based on the withdrawal of male hormones until now. Whether andro-
gen deprivation is achieved surgically or medically, as a result of hypogonadism, we have to count on metabolic syndrome, diabetes, obesity, gynecomastia, cardiovascular diseases, sexual dysfunction, and the deterioration of the muscles and bones. The above mentioned factors not only worsens the quality of life, but also shortens life expectancy. If hormone withdrawal is unavoidable, patients must be informed about the expected advantages of the treatment, and about side effects, risks and the possibilities of their prevention as well. In addition to lifestyle changes, diet, regular and controlled exercises, calcium and vitamin D supplementation, anti-osteoporosis medications are proven to help reduce the rate of osteoporosis.